Introduction: Multiple myeloma

Journal of Managed Care Pharmacy

Volumn 14, Issue 7 SUPPL., 2008, Pages

  Cook, Richard ^a  

^a Blue Cross Blue Shield of Michigan Cardiovascular Consortium   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE;

ADD ON THERAPY; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CONTROL; CANCER PAIN; CANCER REGRESSION; CANCER RELAPSE; CARCINOGENESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; CYTOGENETICS; DRUG DOSE COMPARISON; DRUG MEGADOSE; EDITORIAL; GENE MUTATION; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEALTH STATUS; HUMAN; LABORATORY TEST; MEDICAL DECISION MAKING; MONOTHERAPY; MULTIPLE MYELOMA; PREVALENCE; PROGNOSIS; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 54449084055     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2008.14.s7-a.4     Document Type: Editorial

References (18)

1. Kumar SK, Rajkumar V, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516-20.
2. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-71.
3. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24:431-36.
4. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003; 348:2609-17.
5. Attal M, Harousseau J, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003; 349:2495-502.
6. United States Food and Drug Administration. Bortezomib: supplemental new drug application approval letter (NDA 21-602/S-015). June 20, 2008. Available at www.fda.gov/cder/foi/appletter/2008/021602se1-015ltr.pdf. Accessed June 24, 2008.
7. Rajkumar SV, Jacobus S, Callander N, et al. Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2007;25:LBA8025.
8. Cook R. An economic perspective on treatment options in multiple myeloma. Managed Care Oncol. Spring 2007;3:10-12.
9. Messori A, Trippoli S, Santarlasci B. Pharmacotherapy of multiple myeloma: an economic perspective. Expert Opin Pharmacother. 2003; 4:515-24.
10. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7:585-98.
11. Schwartzberg L. Managed care considerations in the treatment of multiple myeloma. Managed Care Oncol. Spring 2007;3:14-16, 47.
12. Merck Source. Multiple Myeloma: 2003. Available at: www.merck.com/mmhe/ sec14/ch175/ch175c.html. Accessed March 9, 2008.
13. Multiple Myeloma Research Foundation. Intro to myeloma. Available at: www.multiplemyeloma.org/about_myeloma/index.php. Accessed March 9, 2008.
14. Barosi G, Boccadoro M, Cavo M, et al. Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. Haematologica. 2004;89:717-41.
15. The Multiple Myeloma Clinical Practice Guidelines in Oncology (Version 2.2008). National Comprehensive Cancer Network, Inc. Available at www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf. Accessed April 27, 2008.
16. Djulbegovic B, Kumar A. Multiple myeloma: detecting the effects of new treatments. Lancet. 2008;371:1642-44.
17. Appleby C. Payers' costly battle against cancer. Biotechnol Healthcare. June 2005:18-25.
18. Katzel JA, Hari P, Vesole DH. Multiple myeloma: charging toward a bright future. CA Cancer J Clin. 2007;57:301-18.